Metformin efficacy biomarkers
Pro Research Analysisby 
Searched over 200M research papers
Serum N-Glycans as Metformin Efficacy Biomarkers
Recent research has identified serum N-glycans as promising biomarkers for predicting metformin efficacy in patients with type 2 diabetes. Specific N-glycan profiles, particularly the abundance of "peak9" and a combination of 11 other N-glycans at baseline, can distinguish responders from non-responders with good sensitivity and specificity. These glycan changes are more pronounced in patients who respond well to metformin, suggesting their potential value in guiding treatment decisions .
Gut Microbiome Functional Pathways and Metformin Response
The gut microbiome plays a significant role in metformin efficacy. Pre-treatment enrichment of gut microbial functions related to purine degradation and glutamate biosynthesis is associated with better therapeutic response. Additionally, changes in glutamine-associated amino acid metabolism and shifts in bacterial lipidA synthesis and degradation are linked to metformin response. These findings highlight the potential of gut microbiome-encoded metabolic pathways as predictive biomarkers for metformin therapy .
Transcriptomic and Genomic Markers for Metformin Efficacy
Whole-blood transcriptome profiling has revealed that the expression of certain genes, such as IRS2, before metformin treatment is higher in responders. A set of 56 genes can help discriminate between responders and non-responders, explaining a portion of the variability in metformin's therapeutic effect. Additionally, mitochondrial respiratory complex I is implicated in the variability of response . Genomic studies have also identified specific genetic variants (e.g., in LPHN3 and TRPC6) and proteomic markers (such as HAOX1, CCL17, and PAI) that differentiate responders from non-responders, supporting the use of multi-omics approaches for early prediction of metformin efficacy .
Proteomic Biomarkers in Cancer and Inflammatory Conditions
In endometrial cancer, Jupiter microtubule-associated homolog 1 (JPT1) has been identified as a predictive and pharmacodynamic biomarker for metformin response. JPT1 levels are higher in responders and decrease after treatment, suggesting its utility in patient stratification and monitoring . In inflammatory models, metformin alters the abundance of tRNA-derived small RNAs (tsRNAs), which are linked to inflammation and immunity, indicating their potential as biomarkers for metformin's anti-inflammatory effects .
Growth Differentiation Factor 15 (GDF15) as a Metformin Biomarker
Growth differentiation factor 15 (GDF15) is strongly associated with metformin use and its serum concentration reflects the dose of metformin taken. While GDF15 is a reliable biomarker for metformin exposure, there is no convincing evidence that it mediates metformin's effects on reducing the risk of coronary artery disease, cancer, or type 2 diabetes 610.
Pharmacogenomic and Epigenetic Biomarkers
Genome-wide association studies have identified multiple genetic and epigenetic loci associated with metformin response, particularly in cancer models. For example, the E3 ubiquitin ligase STUB1 influences metformin sensitivity by regulating cyclin A degradation. These findings suggest that integrating genetic, epigenetic, and transcriptomic data can uncover novel biomarkers for metformin efficacy, especially in non-diabetic contexts such as cancer .
Proteomic Changes in Non-Diabetic Conditions
In non-diabetic older adults with mild cognitive impairment, metformin treatment leads to significant changes in plasma and cerebrospinal fluid proteins, with several proteins (e.g., AZU1, CASP-3, CCL11, CCL20, IL32, PRTN3, REG1A) showing consistent alterations. These proteins may serve as candidate biomarkers for metformin's effects beyond glycemic control .
Conclusion
A variety of biomarkers—including serum N-glycans, gut microbiome metabolic pathways, transcriptomic and genomic signatures, proteomic markers, and GDF15—have been identified as potential predictors of metformin efficacy. These biomarkers can help personalize metformin therapy, improve patient outcomes, and expand our understanding of metformin's mechanisms in both diabetic and non-diabetic conditions. Further validation in larger and diverse patient populations is needed to confirm their clinical utility.
Sources and full results
Most relevant research papers on this topic